To view the PDF file, sign up for a MySharenet subscription.

LAB - Labat - Reviewed results for the year ended 28 February 2011 and

Release Date: 01/06/2011 14:31
Code(s): LAB
Wrap Text

LAB - Labat - Reviewed results for the year ended 28 February 2011 and Withdrawal of Cautionary Announcement LABAT AFRICA LIMITED Incorporated in the Republic of South Africa (Registration number 1986/001616/06) JSE code: LAB & ISIN: ZAE000018354 ("Labat" or "the company") REVIEWED RESULTS FOR THE YEAR ENDED 28 FEBRUARY 2011 AND WITHDRAWAL OF CAUTIONARY ANNOUNCEMENT GROUP CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME Reviewed Audited 12 months 12 months
28 February 28 February 2011 2010 R`000 R`000 Revenue 27,550 28,108 Continuing operations 27,550 19,375 Discontinued operations - 8,733 Operating loss before depreciation (2,840) (7,141) and amortisation Continuing operations 6,220 8,232 Discontinued operations (9,060) (15,373)
Depreciation (869) (6,363) Continuing operations (394) (1,772) Discontinued operations (475) (4,591)
Operating (loss) before interest and (3,709) (13,504) taxation Continuing operations 5,826 6,460 Discontinued operations (9,535) (19,964) Interest paid (3,274) (4,603) Continuing operations (827) (1,649) Discontinued operations (2,447) (2,954) Interest received 76 350 Continuing operations 58 350 Discontinued operations 18 - (Loss) before taxation, sale and (6,907) (17,757) fair value adjustments Continuing operations 5,057 5,161 Discontinued operations (11,964) (22,918) Discontinued operation-disposal of 20,091 (17,020) investments and fair value adjustments Impairment of plant equipment and - (17,020) inventory Impairment of investment (48) - Reversal of provision for finance 20,139 - costs Profit/(loss) before taxation 13,184 (34,777) Continuing operations 5,057 5,161 Discontinued operations 8,127 (39,938) Taxation - - Continuing operations - - Discontinued operations - - Profit/(loss) after taxation 13,184 (34,777) Continuing operations 5,057 5,161 Discontinued operations 8,127 (39,938) Other comprehensive income - (24,318) Continuing operations gain on building - 2,028 Discontinued operation impairment of property, plant and - (37,218) equipment Income tax relating to components of - 10,872 other comprehensive income
Total comprehensive income/(loss) 13,184 (59,095) for the year Continuing operations 5,057 7,189 Discontinued operations 8,127 (66,284) Attributable to Minority Interest - - Equity holders 13,184 (34,777) Profit attributable to shareholders 13,184 (34,777) Weighted Shares in issue throughout 197,155 197,155 the year (000) Basic profit/( loss) per share 6.7 (17.6) (cents) Continuing operations 2.6 2.6 Discontinued operations 4.1 (20.3) Headline earnings/(loss) per share (cents) 6.2 (13.4) Continuing 2.6 2.6 Discontinuing 3.6 (16.0) Reconciliation of basic to headline earnings Profit/(loss)for the year 13,184 (34,777) Sale of assets (1,076) - Impairment of investment and plant 48 8,214 and equipment Headline earnings/(loss) 12,156 (26,563) Continuing operations Basic / Headline profit 5,057 5,161 Discontinued operations Profit/(loss) for the year 8,127 (39,938) Sale of assets (1,076) - Impairment of investment and plant 48 8,214 and equipment Headline earnings/(loss) 7,099 (31,724) CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION Reviewed Audited 12 months 12 months 28 February 28 February 2011 2010
R`000 R`000 ASSETS Property, plant and equipment 34,548 39,812 Other financial assets 179 179 Non-current assets 34,727 39,991 Inventories 3,091 2,811 Trade and other receivables 5,517 14,569 Cash and cash equivalents 4,777 1,444 Current assets 13,385 18,824 Total assets 48,112 58,815 EQUITY AND LIABILITIES Share capital and reserves (23,344) (36,567) Long-term liabilities 34,020 34,037 Deferred taxation 7,235 7,235 Non-current liabilities 41,255 41,272 Trade and other payables 29,962 53,248 Current portion of financial 56 679 liabilities Taxation 183 183 Current liabilities 30,201 54,110 Total equity and liabilities 48,112 58,815 Number of shares in issue (`000) 197,155 197,155 Total Net asset value per share (11.8) (18.5) (cents) CONDENSED CONSOLIDATED STATEMENT OF CASHFLOWS Reviewed Audited 12 months 12 months 28 February 28 February 2011 2010
R`000 R`000 Net flow from operating activities (425) (10,082) Net flow from investing activities 4,398 2,442 Net flow from financing activities (640) (2,333) Net increase/(decrease) in cash 3,333 (9,973) Cash at beginning of period 1,444 11,417 Cash at end of period 4,777 1,444 CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY R`(000) Share Share Treasury Non Distribu- Total Capital Premium Shares Distribu- table Capital table Reserves and Reserves reserves
Balance at 1 1,972 49,065 (482) - (102,547) (51,992) March 2010 Total - - - - 13,184 13,184 comprehensive income for the year Surplus on - - - 15,464 - 15,464 revaluation of property - after tax effect Balance at 28 1,972 49,065 (482) 15,464 (89,363) (23,344) February 2011 NOTES TO THE FINANCIAL STATEMENTS Reviewed Audited 12 months 12 months
28 February 2011 28 February 2010 R`000 R`000 1. Assets and liabilities relating to the discontinued operations 1.1 SAMES (Wafer manufacturing facility) Plant and 1,027 5,379
equipment Accounts 1,165 1,454 receivable Provisions 5,824 23,816 Provision for Finance Cost 20,139 17,757 Other provisions 5,824 6,059 Less reversal of provision for finance cost (20,139) - 1.2 ELSEC Fixed assets - 28 Cash - 179 Accounts - 848 receivable Stock - 1,536 Trade creditors - (1,543) Intercompany loan (4,554) (3,976) Retained income 4,506 2,928 Loss on disposal (48) - SEGMENTAL REPORTING The Group has adopted IFRS 8 Operating Segments as its segmental reporting standard which requires an entity to report financial and descriptive information about its reportable segments, which are operating segments or the aggregation of operating segments that meet specified criteria. Operating segments are components of an entity in respect of which separate financial information is available is evaluated regularly by management. The Group had two segments which are as follows: Technology which manufactures and distributes integrated circuits (chips) and security hardware. This segment has been discontinued. Head office operations which provide management services to the group. The segments as reported in the segmental analysis are consistent with the internal reports that are provided to the chief operation decision makers. Revenue totals show the other operations revenue for the Group after inter- company elimination of R3.0 million. The Technology segment has not had any extensive reliance on any single customer. Reviewed 28 Audited 28 February 2011 February 2010
R`000 R`000 Revenue by Segment 27 550 28 108 Technology 27 550 28 108 Other operations - - Loss from operations before finance (3 709) (13 504) costs and fair value adjustments by segment Technology (938) (11 271) Other operations (2 771) (2 233) Property, Plant and Equipment by 34 548 39 812 segment Technology 34 516 39 757 Other operations 32 55 Trade and Accounts receivable by 5 517 14 569 segment Technology 5 513 14 365 Other operations 4 204 Trade and Accounts payable by 29 962 53 248 segment Technology 15 698 43 355 Other operations 14 264 9 893 Capital Expenditure - 25 Technology - 25 Other operations - - Depreciation 869 6 363 Technology 845 6 327 Other operations 24 36 COMMENTARY RESULTS The group is pleased to report a set of positive results for the period under review. Headline earnings per share increased to 6.2 cents per ordinary share from a loss of (13.4) cents in the previous year. Total comprehensive income for the year was R13.2 million versus a loss of (R59.1) million in the previous financial year. Continuing Operations The Integrated Circuit ("IC") operations performed well during the year. The transfer of manufacturing to China was completed successfully with one remaining product transfer to be made. Manufacturing in China has proven to be very successful with good margins being maintained. Research and Development For the IC business, exciting new products in the energy measurement and energy management fields are being developed. Existing one micron products are being enhanced and re-designed down to a 0.5 micron platform, with potential to make substantial manufacturing cost savings, which would result in the group`s IC product range becoming much more cost competitive. Discontinuing Operations Discontinued operations relate to the ceasing of operation of the wafer manufacturing facility of SAMES and Elsec, a division of SAMES dealing in security solutions. The SAMES facility in Koedoespoort lends itself to being utilised for a pharmaceutical manufacturing and packaging plant. Currently an in-depth study is being undertaken by Labat and the Industrial Development Corporation to assess the viability of such a business in South Africa. SAMES surplus fixed assets are being disposed of and the proceeds are being used to settle remaining creditors. The de-commissioning exercise will be completed in the next six months and the facility will then be available for conversion to pharmaceutical use. Prospects The current IC business is doing well and its prospects are good. Capacity constraints relating to the closed manufacturing plant no longer exist and our emphasis is now on growing our market and developing new and improved products. Pharmaceuticals The investigation into the conversion of the SAMES facility for pharmaceutical purposes is going well. As mentioned above, the de-commissioning of the old plant is well advanced. Conceptual designs for Active Pharmaceutical Ingredient ("API") and Oral Solid Dosage ("OSD") plants have been prepared and approved. The results of the pre-feasibility study are encouraging and the Company envisages that a profitable API and OSD business, housed in the decommissioned SAMES facilities, can be developed to provide much needed anti-retroviral medicines for the Southern African region. Discussions are ongoing with various industry, technology and funding partners. Concerns about the feasibility of the establishment of an API facility for the manufacture of ARV products in South Africa are diminishing steadily. This is mainly due to the fact that the HIV/Aids pandemic has changed the market horizon completely. The number of HIV/Aids patients being treated in South Africa alone, is expected to increase to 3.5 million by 2016 from the current 1.2 million patients. New technologies and the ability to utilise the decommissioned SAMES facility are assisting in making the overall business case look promising. The Company expects to make a formal decision in the next three months and the market will be advised accordingly. Mining Following the cancellation of the purchase of Primrose Gold Mines (Pty) Limited and the purchase of ERPM from DRD Gold Limited, Labat is still pursuing opportunities in the mining sector. At present investigations are being undertaken with a view to establishing the viability of successfully entering the resources markets. Statement of Compliance and Basis of Preparation The provisional reviewed financial information for the year ended 28 February 2011 has been prepared in accordance with the framework concepts and the measurement and recognition requirements of International Financial Reporting Standards ("IFRS"), the South African Companies Act, as amended and the Listings Requirements of the JSE Limited ("JSE Listings Requirements") and contain the information required by IAS 34: Interim Financial reporting. The results have been prepared in accordance with accounting policies of the group that comply with IFRS and the JSE Listings Requirements and have been consistently applied throughout the Group, to all periods represented in this report. The accounting policies adopted are consistent with those of the annual financial statements for the year ended 28 February 2010. Review Opinion These reviewed condensed consolidated financial statements have been reviewed by the group`s auditors, Ngubane Zeelie Inc, and their unmodified review opinion is available for inspection at the company`s registered office. Withdrawal of Cautionary Shareholders are referred to the cautionary announcements dated 21 April 2011, 08 March 2011, 27 January 2011 and 15 December 2010 and are hereby advised that negotiations have terminated and that the cautionary announcement is hereby withdrawn. Corporate Governance The group subscribes to the values of good corporate governance at all levels and is committed to conducting business with discipline, integrity and social responsibility. Post Balance Sheet Events Management is not aware of any material events which occurred subsequent to the year ended 28 February 2011. Dividends In line with group policy, no dividend has been declared. The directors are not recommending the payment of a dividend until the negative equity position of the group has been reversed. For and on behalf of the board. B G VAN ROOYEN CEO Johannesburg 01 June 2011 Date: 01/06/2011 14:31:00 Supplied by www.sharenet.co.za Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited (`JSE`). The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on, information disseminated through SENS.

Share This Story